.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
US Army
Chubb
Covington
Johnson and Johnson
US Department of Justice
Moodys
Healthtrust
Argus Health
Julphar

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204326

« Back to Dashboard

NDA 204326 describes ADZENYS XR-ODT, which is a drug marketed by Neos Theraps and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the ADZENYS XR-ODT profile page.

The generic ingredient in ADZENYS XR-ODT is amphetamine. There are fifty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the amphetamine profile page.

Summary for 204326

Tradename:1
Applicant:1
Ingredient:1
Patents:4
Formulation / Manufacturing:see details

Pharmacology for NDA: 204326

Suppliers and Packaging for NDA: 204326

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ADZENYS XR-ODT amphetamine TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 204326 NDA Neos Therapeutics, LP 70165-005 70165-005-30 30 BLISTER PACK in 1 CARTON (70165-005-30) > 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
ADZENYS XR-ODT amphetamine TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 204326 NDA Neos Therapeutics, LP 70165-010 70165-010-30 30 BLISTER PACK in 1 CARTON (70165-010-30) > 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORALStrengthEQ 3.1MG BASE
Approval Date:Jan 27, 2016TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jun 28, 2032Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Apr 9, 2026Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Jun 28, 2032Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
US Department of Justice
Cerilliant
Julphar
Deloitte
Novartis
QuintilesIMS
Boehringer Ingelheim
Cipla
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot